- Home
- LENZ vs GYRE Comparison
LENZ vs GYRE Comparison
Compare LENZ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- GYRE
- Stock Information
- Founded
- LENZ 2019
- GYRE 2002
- Country
- LENZ United States
- GYRE United States
- Employees
- LENZ N/A
- GYRE N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- GYRE Health Care
- Exchange
- LENZ Nasdaq
- GYRE Nasdaq
- Market Cap
- LENZ 852.0M
- GYRE 755.7M
- IPO Year
- LENZ 2021
- GYRE N/A
- Fundamental
- Price
- LENZ $31.63
- GYRE $7.80
- Analyst Decision
- LENZ Strong Buy
- GYRE Strong Buy
- Analyst Count
- LENZ 4
- GYRE 2
- Target Price
- LENZ $56.25
- GYRE $17.00
- AVG Volume (30 Days)
- LENZ 1.3M
- GYRE 53.3K
- Earning Date
- LENZ 11-05-2025
- GYRE 11-07-2025
- Dividend Yield
- LENZ N/A
- GYRE N/A
- EPS Growth
- LENZ N/A
- GYRE N/A
- EPS
- LENZ N/A
- GYRE 0.04
- Revenue
- LENZ $17,500,000.00
- GYRE $107,265,000.00
- Revenue This Year
- LENZ N/A
- GYRE $15.25
- Revenue Next Year
- LENZ $285.82
- GYRE $33.14
- P/E Ratio
- LENZ N/A
- GYRE $201.07
- Revenue Growth
- LENZ N/A
- GYRE 2.13
- 52 Week Low
- LENZ $16.54
- GYRE $6.11
- 52 Week High
- LENZ $50.40
- GYRE $14.42
- Technical
- Relative Strength Index (RSI)
- LENZ 55.37
- GYRE 52.84
- Support Level
- LENZ $27.44
- GYRE $7.39
- Resistance Level
- LENZ $26.81
- GYRE $7.81
- Average True Range (ATR)
- LENZ 2.41
- GYRE 0.37
- MACD
- LENZ 1.12
- GYRE -0.01
- Stochastic Oscillator
- LENZ 99.43
- GYRE 59.26
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.